XBIT XBiotech Inc.

4.30
-0.11  -2%
Previous Close 4.41
Open 4.41
Price To book 2.08
Market Cap 152305020
Shares 35,419,772
Volume 695,616
Short Ratio 62.94
Av. Daily Volume 86,108

SEC filingsSee all SEC filings

  1. 8-K - Current report 171086517
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015457
  3. 8-K - Current report 17920184
  4. 8-K - Current report 17902622
  5. 8-K - Current report 17855235

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 commencement of enrollment noted June 26, 2017.
XBIO-101
Endometrial cancer
Phase 2 data released February 16, 2017.
MABp1
Hidradenitis Suppurativa (HS)
Noted November 2016 that Phase 2 trial has been completed and data is being finalized. Noted mid-March 2017 that data will be available soon. No definitive timeline given. Assume some time in 2017.
Xilonix
Pyoderma Gangrenosum
Phase 1/2 top-line data released April 3, 2017. 4 patient deaths noted.
514G3
Staphylococcus Aureus Bacteremia
Phase 3 interim analysis announced June 9, 2017 - trial to be terminated due to lack of efficacy.
Xilonix
Colorectal cancer

Latest News

  1. XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
  2. XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board
  3. XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference
  4. XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
  5. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc.
  6. XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
  7. Robbins Arroyo LLP: XBiotech Inc. (XBIT) Misled Shareholders According to a Recently Filed Class Action
  8. These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?
  9. Today's Research Reports on Stocks to Watch: Xbiotech and GTx
  10. Biotech Movers: Coherus, XBiotech, Flexion
  11. XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis
  12. Why XBiotech Inc. (XBIT) Could Shock the Market Soon
  13. Why XBiotech Inc Jumped Higher Today
  14. XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting
  15. Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Ca...

SEC Filings

  1. 8-K - Current report 171086517
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015457
  3. 8-K - Current report 17920184
  4. 8-K - Current report 17902622
  5. 8-K - Current report 17855235
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830933
  7. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17796977
  8. DEF 14A - Other definitive proxy statements 17796871
  9. 8-K - Current report 17793059
  10. 8-K - Current report 17773910